Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files

Area of Science:

• Oncology
• Radiopharmaceutical Therapy
• Drug Development

Background:

• Targeted radiopharmaceutical conjugates are key therapeutic agents, comprising a radionuclide, chelator/linker, and targeting molecule.
• The National Cancer Institute (NCI) has approved four radiopharmaceutical drug products within this class.
• The NCI is refining its role as a sponsor for investigational new drugs in radiopharmaceutical clinical development.

Purpose of the Study:

• To present the NCI's perspective on the utility of modular radiopharmaceutical drug master files.
• To outline the NCI's strategy for initiating a clinical development program for radiopharmaceutical agents.
• To detail the organization of the NCI's radiopharmaceutical Small Business Innovation Research (SBIR) portfolio.

Main Methods:

• Review of the NCI's experience with radiopharmaceutical drug products.
• Consideration of the advantages of modular drug master files.
• Strategic planning for clinical development and research portfolio organization.

Main Results:

• The NCI acknowledges the potential of modular radiopharmaceutical drug master files.
• A framework is being established for the NCI's engagement in radiopharmaceutical clinical trials.
• The NCI's SBIR portfolio for radiopharmaceuticals is being strategically aligned.

Conclusions:

• Modular radiopharmaceutical drug master files offer a promising regulatory pathway.
• The NCI's approach will facilitate the advancement of targeted radiopharmaceutical therapies.
• Strategic organization of research and development is crucial for therapeutic innovation.